A panel of experts recommended in March that the FDA approve Provenge. But in May, the agency instead asked for more evidence that the vaccine works after specialists … questioned its effectiveness…. The FDA's surprise decision unleashed a spasm of criticism by prostate-cancer patients, advocacy groups and investors in Dendreon [Corp.]. (Washington Post, Friday)
Killing with kindness.
FEE Timely Classic
The FDA Cannot Be Reformed (pdf) by Arthur E. Foulkes Jr.